Prime Medicine Resolves Arbitration with Beam Therapeutics
Prime Medicine (NASDAQ:PRME) has reached a favorable resolution in its arbitration case against Beam Therapeutics, confirming that it did not breach their 2019 collaboration agreement. The tribunal ruled PM647 is within the defined scope of Prime's 'Field' and no damages are owed to Beam.
Topics: arbitration collaboration_agreement genetic_therapies